Literature DB >> 10561180

Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children.

L C Kremer1, M M Tiel-van Buul, M C Ubbink, M Offringa, J Ottenkamp, R V Olmos, P A Voûte.   

Abstract

PURPOSE: To determine the value of indium-111-antimyosin ((111)In-AM) scintigraphy in the early detection of myocardial damage in children treated with doxorubicin. PATIENTS AND METHODS: Twelve planar scintigrams were made of eight patients (seven children and one young adult; mean age, 12 years). Three scans were obtained before doxorubicin therapy in three patients, and nine scans were obtained during doxorubicin therapy in seven patients. The heart-to-lung ratio (HLR) was calculated. Left ventricular function was assessed by echocardiography before and during therapy by measuring the fractional shortening (FS).
RESULTS: The HLR of the three baseline scans was below 1.5, within the normal range for adults. Six of the seven patients whose scans were obtained during chemotherapy had abnormal HLR values (> 1.5). One patient had severe myocyte damage and showed an early increase in the HLR (2.3) after a cumulative doxorubicin dose of 150 mg/m(2). The FS measured by echocardiography was normal throughout therapy, and the final cumulative dose of doxorubicin was 450 mg/m(2). This patient developed fatal clinical heart failure 3 months after completion of chemotherapy. In one patient, who was pretreated with the cardioprotective agent dexrazoxane, the HLR remained within normal limits during therapy.
CONCLUSION: (111)In-AM scintigraphy seems to be suitable to detect early myocardial damage after a cumulative doxorubicin dose of 150 mg/m(2 )in children and may be useful for identifying children who are at increased risk of developing cardiac sequelae.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10561180     DOI: 10.1200/JCO.1999.17.4.1208

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  4 in total

1.  Myocardin mRNA is augmented in the failing myocardium: expression profiling in the porcine model and human dilated cardiomyopathy.

Authors:  Mario Torrado; Eduardo López; Alberto Centeno; Constancio Medrano; Alfonso Castro-Beiras; Alexander T Mikhailov
Journal:  J Mol Med (Berl)       Date:  2003-08-13       Impact factor: 4.599

Review 2.  Comprehensive review on cardio-oncology: Role of multimodality imaging.

Authors:  Carol Chen-Scarabelli; Chad McRee; Massoud A Leesar; Fadi G Hage; Tiziano M Scarabelli
Journal:  J Nucl Cardiol       Date:  2016-05-25       Impact factor: 5.952

Review 3.  Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively.

Authors:  Ronald G Schwartz; Diwakar Jain; Eugene Storozynsky
Journal:  J Nucl Cardiol       Date:  2013-06       Impact factor: 5.952

Review 4.  Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers.

Authors:  Joseph A Sparano; David L Brown; Antonio C Wolff
Journal:  Drug Saf       Date:  2002       Impact factor: 5.228

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.